Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

How pharmacoeconomics should be applied to support decisions in lower income European countries? (CROSBI ID 620262)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Kalo, Zoltan ; Vitezić, Dinko How pharmacoeconomics should be applied to support decisions in lower income European countries? // Abstract Book, First Macedonian and Fourth Adriatic Congress on Pharmacoeconomics and Outcomes Research / Suturkova, Ljubica ; Vitezić, Dinko (ur.). 2014. str. 11-11

Podaci o odgovornosti

Kalo, Zoltan ; Vitezić, Dinko

engleski

How pharmacoeconomics should be applied to support decisions in lower income European countries?

As health care resources are limited all over the world, reimbursement and formulary listing of new medicines is subject to their cost-effectiveness and affordability in more and more countries. The need for pharmacoeconomic evidence fundamentally changes the algorithm of coverage decisions, therefore medical professionals and policymakers have to be familiar with the principles of pharmacoeconomics, including advantages and limitations of different approaches to estimate the health benefit, cost-effectiveness and budget impact of medicines and the transferability of results among countries. Synthesis of scientific evidence provides better understanding of stakeholders on the real value of innovative medical technologies. The value proposition of health technologies are illustrated by different case studies in the workshop. In lower income European countries the major bottleneck of implementation evidence based health policy are the lack of trained health economists and local data for the adaptation of international economic models. The workshop provides practical guidance for the collection of local data in pharmacoeconomic analyses.

health care resources; reimbursement; new medicines; cost-effectiveness; pharmacoeconomic analyses

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

11-11.

2014.

objavljeno

Podaci o matičnoj publikaciji

Abstract Book, First Macedonian and Fourth Adriatic Congress on Pharmacoeconomics and Outcomes Research

Suturkova, Ljubica ; Vitezić, Dinko

Podaci o skupu

First Macedonian and Fourth Adriatic Congress on Pharmacoeconomics and Outcomes Research

pozvano predavanje

24.04.2014-27.04.2014

Ohrid, Sjeverna Makedonija

Povezanost rada

Kliničke medicinske znanosti